Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 2/2003

01-09-2003 | Meeting abstract

Efficacy of recombinant human interferon-alfa2a on ocular and extra-ocular manifestations of Behçet's disease and influence on cells of the immune system: results of an open four center trial

Authors: I Kötter, M Treusch, R Vonthein, M Zierhut, A Eckstein, T Ness, I Günaydin, B Grimbacher, S Blaschke, HH Peter, N Stübiger

Published in: Arthritis Research & Therapy | Special Issue 2/2003

Login to get access

Excerpt

Behçet's disease (BD) is a multisystem vasculitis of unknown origin. Standard treatment comprises systemic immunosuppressive agents. In a study primarily designed for refractory ocular disease we additionally evaluated the efficacy of recombinant human interferon-alpha2a (rhIFN-alpha2a) for the extraocular manifestations. …
Metadata
Title
Efficacy of recombinant human interferon-alfa2a on ocular and extra-ocular manifestations of Behçet's disease and influence on cells of the immune system: results of an open four center trial
Authors
I Kötter
M Treusch
R Vonthein
M Zierhut
A Eckstein
T Ness
I Günaydin
B Grimbacher
S Blaschke
HH Peter
N Stübiger
Publication date
01-09-2003
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 2/2003
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar980

Other articles of this Special Issue 2/2003

Arthritis Research & Therapy 2/2003 Go to the issue

Meeting abstract

A review on disease activity scores in Behçet's disease (BD)

Meeting abstract

Cytotoxic drugs in ocular lesions of Behçet's disease

Meeting abstract

Viral infection of retinal pigment epithelium: a possible role for initiation of Behçet's disease

Meeting abstract

Immunosuppressive effects of gemcitabine in the HSV-induced Behçet's disease like mouse model

Meeting abstract

The use of interferon-alfa in Behçet's disease: review of the literature

Meeting abstract

Introduction
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits